We provide individually tailored Real World Evidence services to different industry and healthcare actors in Finland and the Nordics. Our scientific experts and data scientists ensure that the correct research methods and data sources are used to answer your questions.
Real World Evidence (RWE) can be used to demonstrate the value of a certain treatment or technology for patients, healthcare service providers and society. Due to comprehensive healthcare, data in digital format, a personal ID, and progressive research legislation, Finland is a true model country for Real World Evidence studies.
Medaffcon experts have solid experience from all life cycle stages of a product, whether it is communication towards payers, showing the clinical value or demonstrating the impact through data-driven value tools. Our broad expertise is at your service when planning and executing real world evidence studies and strategies. We identify the correct data sources and analysis methods to support your evidence need. Click each topic for more information.
Examples of our RWE services
Long term strategic RWE input
We offer strategic Real World Evidence (RWE) input throughout the lifecycle of your product identifying data gaps and the best opportunities to show value, whether for payer negotiations, clinical decision making or post-marketing real world effectiveness. We help you stay up to date with your evidence generation strategy to provide you with the best tools for success.
Workshops to identify your data gaps and needs
We offer our customers Real World Evidence (RWE) workshops where we together define data gaps and needs in selected therapeutical areas or products and generate a real world evidence plan.
We assess together with our customers the Real World Data (RWE) needs and gaps and generate a Real World Evidence plan
Identify data sources to address the identified data needs
Recognize the various strategic utilization targets of RWE
Execution of RWE strategy and project management
We offer our customers comprehensive services to generate Real World Evidence (RWE), including all aspects from (pre-)planning to publication and beyond. The services include
Strategic advice and support – advice and support for your Real World Evidence strategy and insight on the Finnish and Nordic Real World Data landscape
Planning – defining study objectives, identifying data sources and the most suitable study design
Study execution – project management, protocol development, study approval application, and data analysis
Publications and communication – scientific writing and content creation
Post study activities – utilizing results to the fullest, updating RWE strategy
FastTrack data requests
A full-scale Real World Evidence study is not always the optimal solution, both cost and timewise. For light and defined data needs, FastTrack requests may be the better approach. If you have a specific data need in mind, please contact us to plan the opportunities and discuss strategies.
Data driven interactive value tools
Data from various sources, including RWE studies, clinical trials and sales data, can be processed to a user-friendly format and used in communication with internal and external stakeholders. We help you make the most out of your data for informed decision making, utilizing our interactive value tools.
HEOR and market access evidence
Real world data is often used in health economic analyses to support market access and health care decision making. Our experts support your evidence generation process from defining the research question to generating health economic evidence for payer and decision-maker discussions.
Medaffcon has the most extensive experience in analyzing and utilizing RWE in Finland. We have conducted over 100 RWE projects since 2013. Our RWE studies are closely related to health economic perspectives on interventions and clinical outcomes. In addition, we are closely involved in supporting and developing unique data sources in Finland. We also provide Nordic services through our network of close collaborators.
Lets build together a RWE entity to meet your needs!
Watch a video introduction of our Real World Evidence services:
Why Real World Evidence?
Real World Evidence can be used to understand patient populations, treatments and outcomes and the standard of care to assist clinical decision making. Increasingly, payers want evidence on current care, disease burden and treatment effectiveness in a real world patient population. Below are some typical settings where RWE studies are valuable.
Local data on patient numbers, outcomes, treatments and healthcare resource utilization are crucial aspects for cost-effectiveness and all stakeholders, especially the payer. This data is increasingly being utilized in budget impact and cost-effectiveness analyses to reduce the ever present uncertainty in health economic analyses.
In addition, showing the effectiveness in real life after the medication’s market entry is also becoming increasingly important. Real World Evidence studies can readily assess these topics.
Information on incidence and prevalence, as well as the survival of patients and patient subgroups, may sound trivial, but often there is a lack of recent data on these. Patient numbers are of significance for the healthcare system when planning care, for the payer to assess the budget impact and for the marketing company when planning new launches.
HEOR and Market Access
Real World Evidence is highly appreciated and often mandatory in negotiations with payers. Further, current treatment and outcomes and questions on healthcare resource utilisation can be assessed with Real World Evidence studies or FastTrack requests.
Data from RWE publications and other sources can also be used in discussions with decision makers and can be processed to a user-friendly format utilizing our interactive value tools.
Virtual control arms, standard of care
Standard of care and outcomes are essential to understand when a new product enters the market, both from a clinical and payer perspective. Especially oncology drugs and treatments can enter the market with phase 2 data as clinical evidence.
A control group for a clinical trial can be generated from retrospective registry data. This control group is called a virtual control arm. Patients in the virtual control arm are selected from registry data using the selection criteria of the clinical trial. Virtual control arms are used to supplement one and two armed clinical trials with Real World Evidence.
In some cases virtual control groups are formed because a clinical trial would be unethical. For example, in the case of cancer medicines patients cannot be left without treatment. Virtual control arms aim to act as comparators receiving standard of care when assessing the same outcomes as in the patients treated in clinical trials.
We at Medaffcon have conducted successful virtual control arm studies. Contact us, if you want to discuss more!
Patients move between primary and specialty care, and treatment pathways may be intricate and variable by region. The overview of the treatment pathway can be assessed in studies, including occupational healthcare, to gain a holistic view of differences and optimal approaches in care.
Clinical decision making
Real World Evidence studies can describe patient population subgroups and identify those that may gain most of some treatments or to detect groups in need of intensiﬁed monitoring. These results may guide healthcare resource allocations.
Regional difference in healthcare utilization and patient outcomes, incidence and prevalence, can be studied both within Finland, and across the Nordics to gain insight into how the care is organized.
Stakeholder communication and interaction
Medaffcon can manage the publication process of the Real world evidence studies.
The vast amount of data behind the real-life evidence, publications and sales contain valuable information that can transform into visually pleasant interactive communication tools.
After a drug has become available for patients, information on patient adherence to different medications and treatment persistence is of importance for a successful treatment. These aspects can be assessed in Real World Evidence studies to guide treatment and evaluate the impact on real world effectiveness.
Data from different sources
Finland and the Nordics have some unique Real World Data opportunities, with a base in a long tradition of longitudinal data from electronic medical records. Many data sources are national, covering the whole population, whereas in-depth analyses on hospital administered drugs and outcomes, can be studied at regional data lakes. The different data sources can be combined utilizing a unique personal identification number. Our scientific experts and data scientists ensure that the correct research methods and data sources are used to answer your questions.
Typical RWE study process
We help you identify the relevant data sources and plan the whole study together with you from protocol development and submission to authorities to data analysis, reporting, publication and beyond.
RWE studies produce scientific articles
Medaffcon’s RWE studies have been featured on numerous scientific publications across different specialty fields. Read summaries of some of our studies below and check out our publications here:
Mariann joined Medaffcon’s team in 2016 after finishing her PhD. The transition to real world evidence (RWE) research was a natural continuum to her previous research career. Through RWE studies, she has had the privilege to gain a broad insight into working with different stakeholders within the healthcare field. The vast proportion of her days goes towards interacting with clients, planning and performing RWE studies, and supporting Medaffcon’s RWE team. Subjects that keep her work interesting are the vast variability of customers and projects, problem-solving, and interacting with people.
“The number of RWE studies has increased since stakeholders within the healthcare industry have an increasing demand for knowledge-based decision making tools that need to be fulfilled. The future, therefore, has an ever-increasing emphasis on RWE”.
Iiro joined Medaffcon in March 2017 as a Biostatistician. For the preceding four years, he has worked as a research assistant in an academic study group, analyzing clinical and genetic patient data. Iiro holds a Master of Science degree in Technology in Bioinformation Technology.
Iiro’s strengths include his strong expertise in statistics and data-analysis, hands-on experience in working with sensitive patient data, and strong interdisciplinary communication skills with experts from various fields. In the field, he is particularly interested in the large data amounts made available with the revolution of technology and how the information received such data can potentially be utilized to draw concrete conclusions, both in order to understand the nature of diseases and to advance the goals of the pharmaceutical industry and patient treatment.
“Machine learning and AI-based solutions will have a major impact on the healthcare sector now and in the future. However, effectively utilizing the already collected and available health-data will have a higher importance in order to improve health-care”.